Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression

Decitabine (DAC), a DNA methyltransferase (DNMT) inhibitor, is tested in combination with conventional anticancer drugs as a treatment option for various solid tumors. Although epigenome modulation provides a promising avenue in treating resistant cancer types, more studies are required to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Buocikova, Verona, Tyciakova, Silvia, Pilalis, Eleftherios, Mastrokalou, Chara, Urbanova, Maria, Matuskova, Miroslava, Demkova, Lucia, Medova, Veronika, Longhin, Eleonora Marta, Rundén-Pran, Elise, Dusinska, Maria, Rios-Mondragon, Ivan, Cimpan, Mihaela Roxana, Gabelova, Alena, Soltysova, Andrea, Smolkova, Bozena, Chatziioannou, Aristotelis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585938/
https://www.ncbi.nlm.nih.gov/pubmed/36278182
http://dx.doi.org/10.3389/fphar.2022.991751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585938/
https://www.ncbi.nlm.nih.gov/pubmed/36278182
http://dx.doi.org/10.3389/fphar.2022.991751

Ejemplares similares